Kazia Expands Pipeline with SETDB1 Platform and MSETC, Plans $6M IND Spend
Kazia Therapeutics has in-licensed a first-in-class SETDB1-targeted epigenetic platform including lead candidate MSETC, a selective bicyclic peptide designed to restore immune signaling in immunotherapy-resistant tumors. The global-rights agreement carries a $1.39 million upfront payment and outlines $6 million planned IND-enabling spend over 18 months.
1. In-Licensing Deal
Kazia has acquired global rights to a SETDB1-targeted epigenetic drug development platform from QIMR Berghofer for an upfront payment of $1.39 million and a tiered revenue-sharing agreement, with no clinical or regulatory milestone obligations.
2. MSETC Lead Candidate and AI Engine
The platform includes an AI-integrated drug discovery engine and lead candidate MSETC, a highly selective bicyclic peptide designed to target the nuclear SETDB1 complex and restore interferon signaling in tumors resistant to checkpoint inhibitors.
3. Development Path and Costs
Kazia plans to advance the SETDB1 program alongside its PD-L1 degrader platform through IND-enabling studies over the next 18 months, allocating approximately $6 million in R&D spend, with significant Australian tax incentives expected to offset costs.
4. Market Opportunity and Partnerships
The global epigenetic therapeutics market is estimated at $15–20 billion annually and Kazia anticipates strategic partnerships to leverage the broad applicability of SETDB1 inhibition across aggressive, treatment-refractory cancers.